The rewiring of cell cycle control by the frequent inactivation of TP53 and CDKN2A in early carcinogenesis of HNSCC, is an excellent approach for targeted treatment of tumors and precancerous mucosal changes. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.